BioNTech (BNTX) Stock Price, News & Analysis

Company Overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Key Stats

• Today's Range: $117.26 to $119.75
• 50-Day Range: $78.36 to $124.71
• 52-Week Range: $76.53 to $131.49
• Volume: 518,699 shs
• Average Volume: 797,218 shs
• Market Capitalization: $27.92 billion
• P/E Ratio: 234.82
• Dividend Yield: N/A
• Price Target: $127.15
• Consensus Rating: Moderate Buy

BioNTech Stock Analysis - MarketRank™

BioNTech scored higher than 36% of companies evaluated by MarketBeat, and ranked 569th out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioNTech has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioNTech are expected to grow in the coming year, from ($2.87) to ($2.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioNTech is 236.26, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 131.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioNTech is 236.26, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 117.87.

Price to Book Value per Share Ratio

BioNTech has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.13% of the float of BioNTech has been sold short.

Short Interest Ratio / Days to Cover

BioNTech has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioNTech has recently increased by 3.88%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioNTech does not currently pay a dividend.

Dividend Growth

BioNTech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.13% of the float of BioNTech has been sold short.

Short Interest Ratio / Days to Cover

BioNTech has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioNTech has recently increased by 3.88%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.78

News Sentiment

BioNTech has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for BioNTech this week, compared to 10 articles on an average week.

Search Interest

49 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 206% compared to the previous 30 days.

MarketBeat Follows

9 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioNTech insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.52% of the stock of BioNTech is held by institutions.

BNTX Stock Analysis - Frequently Asked Questions

How have BNTX shares performed this year?

BioNTech's stock was trading at $105.54 at the beginning of 2024. Since then, BNTX stock has increased by 11.9% and is now trading at $118.13.
View the best growth stocks for 2024 here.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) released its quarterly earnings data on Monday, August, 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by $1.34. The business's revenue was down 23.3% compared to the same quarter last year.

Does BioNTech have any subsidiaries?

BioNTech subsidiaries include these companies: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and others.

When did BioNTech IPO?

BioNTech (BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Who are BioNTech's major shareholders?

BioNTech's top institutional shareholders include Baillie Gifford & Co. (3.48%), Primecap Management Co. CA (2.01%), Deerfield Management Company L.P. Series C (0.25%) and Candriam S.C.A. (0.24%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 8/05/2024
• Today: 9/25/2024
• Next Earnings (Estimated): 11/04/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BNTX
• CUSIP: N/A
• CIK: 1776985
• Web: www.biontech.de
• Phone: 49-61-31908-40
• Fax: 49-6131-908-4390
• Employees: 6,133
• Year Founded: 2008

Price Target and Rating

• Average Stock Price Target: $127.15
• High Stock Price Target: $171.00
• Low Stock Price Target: $85.00
• Potential Upside/Downside: +7.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 14 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.50
• Trailing P/E Ratio: 236.94
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.01 billion
• Net Margins: -18.69%
• Pretax Margin: -8.75%
• Return on Equity: -2.54%
• Return on Assets: -2.24%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 7.54
• Quick Ratio: 7.40

Sales & Book Value

• Annual Sales: $2.69 billion
• Price / Sales: 10.47
• Cash Flow: $6.05 per share
• Price / Cash Flow: 19.58
• Book Value: $92.17 per share
• Price / Book: 1.29

Miscellaneous

• Outstanding Shares: 237,726,000
• Free Float: 192,083,000
• Market Cap: $28.16 billion
• Optionable: Optionable
• Beta: 0.23